NO20042730L - Anvendelse av en farnesylproteintransferaseinhibitor i kombinasjon med andre antineoplastiske midler til fremstilling av et medikament mot kreft - Google Patents

Anvendelse av en farnesylproteintransferaseinhibitor i kombinasjon med andre antineoplastiske midler til fremstilling av et medikament mot kreft

Info

Publication number
NO20042730L
NO20042730L NO20042730A NO20042730A NO20042730L NO 20042730 L NO20042730 L NO 20042730L NO 20042730 A NO20042730 A NO 20042730A NO 20042730 A NO20042730 A NO 20042730A NO 20042730 L NO20042730 L NO 20042730L
Authority
NO
Norway
Prior art keywords
preparation
combination
cancer drug
antineoplastic agents
protein transferase
Prior art date
Application number
NO20042730A
Other languages
English (en)
Inventor
David L Cutler
Michael L Meyers
Charles Baum
Sara L Zaknoen
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20042730L publication Critical patent/NO20042730L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20042730A 2001-11-30 2004-06-29 Anvendelse av en farnesylproteintransferaseinhibitor i kombinasjon med andre antineoplastiske midler til fremstilling av et medikament mot kreft NO20042730L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33441101P 2001-11-30 2001-11-30
PCT/US2002/037954 WO2003047697A2 (en) 2001-11-30 2002-11-25 Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer

Publications (1)

Publication Number Publication Date
NO20042730L true NO20042730L (no) 2004-06-29

Family

ID=23307076

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042730A NO20042730L (no) 2001-11-30 2004-06-29 Anvendelse av en farnesylproteintransferaseinhibitor i kombinasjon med andre antineoplastiske midler til fremstilling av et medikament mot kreft

Country Status (13)

Country Link
US (2) US20030185831A1 (no)
EP (1) EP1448268A2 (no)
JP (1) JP2005511663A (no)
CN (2) CN1617755A (no)
AU (1) AU2002352941A1 (no)
BR (1) BR0214564A (no)
CA (1) CA2468839A1 (no)
HU (1) HUP0402401A2 (no)
MX (1) MXPA04005207A (no)
NO (1) NO20042730L (no)
NZ (1) NZ532562A (no)
WO (1) WO2003047697A2 (no)
ZA (1) ZA200403737B (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1551408A1 (en) * 2002-07-24 2005-07-13 Novartis AG 4-(4-methylpiperazin-1-ylmethyl)-n- 4-pyridin-3-yl)pyrimidin -2-ylamino)phenyl -benzamide for treating anaplastic thyroid cancer
CA2439440A1 (en) * 2002-09-05 2004-03-05 Emory University Treatment of tuberous sclerosis associated neoplasms
BRPI0416316A (pt) * 2003-11-06 2007-01-09 Schering Corp combinação de um inibidor da farnesil transferase com um agente anti-hormonal para o tratamento de cáncer de mama
AU2005216898A1 (en) * 2004-02-26 2005-09-09 The Penn State Research Foundation Combinatorial therapies for the treatment of neoplasias using the opioid growth factor receptor
US20060205810A1 (en) * 2004-11-24 2006-09-14 Schering Corporation Platinum therapeutic combinations
WO2007042465A2 (en) * 2005-10-07 2007-04-19 Novartis Ag Combinati0n of nilotinib with farnesyl transferase inhibitors
EP2076263A2 (en) * 2006-10-25 2009-07-08 Schering Corporation Discontinuous methods of treating cancer
EP2088862A4 (en) * 2006-11-28 2009-12-02 Smithkline Beecham Cork Ltd METHOD OF TREATING CANCER
WO2024100093A1 (en) 2022-11-09 2024-05-16 Merck Patent Gmbh Toll-like receptor 7 agonists as immune-stimulators to elicit the innate antitumor immunity

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874442A (en) * 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
US6096757A (en) * 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
TW581763B (en) * 1997-12-22 2004-04-01 Schering Corp Combination and pharmaceutical composition comprising FPT inhibitor for treating proliferative diseases
US6316462B1 (en) * 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
CA2396865C (en) * 2000-02-04 2009-04-14 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitors for treating breast cancer
ATE375794T1 (de) * 2000-02-24 2007-11-15 Janssen Pharmaceutica Nv Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs
EP1265611A2 (en) * 2000-02-29 2002-12-18 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with taxane compounds
AU2001244166A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
AR033680A1 (es) * 2000-08-30 2004-01-07 Schering Corp Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales
BR0114430A (pt) * 2000-10-05 2004-01-06 George Q Daley Processos para a indução da morte de células cancerìgenas e para a regressão de tumor

Also Published As

Publication number Publication date
HUP0402401A2 (hu) 2005-03-29
AU2002352941A1 (en) 2003-06-17
CA2468839A1 (en) 2003-06-12
US20060183765A1 (en) 2006-08-17
JP2005511663A (ja) 2005-04-28
US20030185831A1 (en) 2003-10-02
CN1617755A (zh) 2005-05-18
BR0214564A (pt) 2004-11-09
WO2003047697A2 (en) 2003-06-12
MXPA04005207A (es) 2004-08-19
ZA200403737B (en) 2005-05-23
WO2003047697A3 (en) 2003-10-30
NZ532562A (en) 2007-02-23
EP1448268A2 (en) 2004-08-25
CN101181269A (zh) 2008-05-21

Similar Documents

Publication Publication Date Title
EE04579B1 (et) Farnesüülproteiintransferaasi inhibiitorite kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette nähtud artropaatiate raviks
DK1204410T3 (da) Farmaceutisk doseringsform med flere komponenter
NO20030627L (no) Hydrogel-drevet medikament doseringsform
DE69907977D1 (de) Pyrrolobenzodiazepine
ATE395053T1 (de) Pharmazeutische salze von 1-phenyl-3- dimethylamino-propan-verbindungen
NO20003219D0 (no) Oralfarmasøytisk doseringsform med pulsert frigivningsvirkning
NO20032909D0 (no) Glukopyranosyloksypyrazolderivater samt medikamentell anvendelse derav
ID28427A (id) Benda penyerap cairan tubuh sekali pakai
ATE296619T1 (de) Feste orale dosierungsform von simethicon
EE200100717A (et) Indasooliühendid ja farmatseutilised kompositsioonid proteiini kinaaside inhibeerimiseks ja meetodid nende kasutamiseks
NO20021329L (no) Kinaseinhibitorer som terapeutiske midler
ITTO20010008A0 (it) Formulazione farmaceutica
NO20022970L (no) Hydrogel-drevet medikamentdoseringsform
NO20034439L (no) Benzamidinderivater
NO20033384D0 (no) Farmasöytisk formulering
DE60127002D1 (de) Pharmazeutische zusammensetzung
ATE403432T1 (de) Pharmazeutische darreichungsform mit gesteuerter freigabe eines cholesterylester- transferproteininhibitors
ATE320244T1 (de) Pharmazeutische zusammensetzungen mit amlodipinmaleat
NO20033785D0 (no) Farmasöytisk formulering
EE05020B1 (et) Glburiidi ravimkoostis
EE05333B1 (et) Makroliidhendite konjugaadid p?letikuvastaste henditega ja nende kasutamine
EE05543B1 (et) Tuumorinekroositeguri antagonisti kasutamine endometrioosi raviks ette n„htud farmatseutilise kompositsiooni valmistamiseks
NO20042730L (no) Anvendelse av en farnesylproteintransferaseinhibitor i kombinasjon med andre antineoplastiske midler til fremstilling av et medikament mot kreft
FI20000780A (fi) Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
DE60217390D1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application